Replies to post #4951 on Skye Bioscience Inc (SKYE)

[TheMonolith]

http://s2.q4cdn.com/753474459/files/doc_presentations/2018/NemusBioscience18bw-CEOCFOMagazine-Interview.pdf

I think what separates Nemus from other companies developing cannabinoids is that our cannabinoids are
both chemically and biosynthetically derived. We are the only company developing across the spectrum of our pipeline,
biosynthetically derived API (Active Pharmaceutical Ingredients) through our 2016 affiliation with Teewinot Life Sciences
and Albany Molecular Research Inc.

Nemus has licensed bio-engineered cannabinoids to make them more
hydrophilic or water soluble to give these molecules versatility for routes of administration that can potentially avoid firstpass
metabolism in the liver and the irregularities that are associated with oral administration of cannabinoids. On a
molecular or cellular level, having these molecules be more hydrophilic also allows them to transfer across membranes
better and there is no better example of this than our pro-drug of THC being used in the eye for glaucoma. If you were to
take pure THC and make it into an eye-drop, it would resemble a drop of cooking oil. It hits the outer barrier of the eye, the
cornea, and very little of that drug reaches key organs in the eye. Whereas, if you use a pro-drug approach with THC, the
drug not only can get into the anterior chamber of the eye but we also find that the drug is able to penetrate into the
posterior chamber of the eye as well. That is very important because the eye is very dense with cannabinoid receptors,
especially CB-1 receptors located on the organs that regulate intraocular pressure in the eye which is key in treating
glaucoma. By virtue of re-engineering these molecules to be more hydrophilic, we have the versatility of an ocular
formulation for the eye, developing an intranasal spray, working on embedding the drug in a matrix so that it can be used
for buccal administration, which is essentially a tape that adheres to the gingiva or gum in your mouth, and dissolves over
fifteen or twenty minutes with the cannabinoid absorbed directly into the blood stream, avoiding the GI track. We also
have the ability for transdermal administration as well as trans-membranous administration, either by a rectal or vaginal
suppository. Bio-engineering provides great options on potential routes of administration.

[zenvesting]

Biosynthesis is cheaper, faster, and offers better quality control.

Cheaper because less energy inputs and time are needed for biosynthesis, faster life cycle means greater production can be achieved in less time, and quality control means specific compounds can be developed without contamination from other plant-derived contaminants.

That's not to mention that the term "CBD Oil" typically refers to a mixture composed primarily of cannabidiol, but also consisting of several minor cannabinoid constituents like CBC and CBG, which are two canabanoids Nemus indicates are responsible for analgesic affects. These compounds come in trace concentrations in plant material, but can be concentrated and refined more in a biosynthesis process.